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RESULTS: Under baseline GI complication annual risk
assumptions (1.5% for NSAIDs), cost savings for cele-
coxib ($10,000 per 100 patients) through avoided GI
events were dominated by the additional drug costs
($66,000 per 100 patients). This relationship held true
even when higher costs NSAIDs, based solely on either
diclofenac or naproxen, and higher underlying rates of
6% were considered. Cost effectiveness ratios were cal-
culated at $41,824 per life year gained under baseline
conditions. Sensitivity analysis showed, however, that
underlying annual risk of GI-related complication had a
strong inﬂuence on the cost-effectiveness of the COX-2
inhibitors. At 3% per year risk levels, the cost per LYG
reduced to $17,107.
CONCLUSION: The analysis suggests that the coxibs
have an attractive cost-effectiveness proﬁle when patients
have an underlying annual risk of GI-related complica-
tions on NSAIDs of at least 2.5% (equivalent to a patient
having at least two recognised risk factors).
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OBJECTIVES: Osteoporosis is a major public health
problem in Asia. The objectives of this study were to
compare the cost-effectiveness of different pharmaceuti-
cal treatments for Hong Kong women with established
osteoporosis.
METHODS: We compared the cost-effectiveness of 
treatments using a decision analytic model based upon
Markov process for a hypothetical cohort of women at
risk of fractures due to osteoporosis. A cohort of 100,000
postmenopausal women were simulated and followed 
for 10 years of treatment. The model included a number
of scenarios based upon available pharmaceutical treat-
ment alternatives in costs, clinical effectiveness, and time
of treatment onset. Sensitivity analyses were performed to
test the robustness of results.
RESULTS: Programme costs, economic beneﬁts, and
cost-effectiveness ratios varied signiﬁcantly among dif-
ferent treatments. Calcium and Alendronate are more
cost-effectives than Calcitonin. Treatment efﬁciency has
signiﬁcant impact on the overall cost-effectiveness of the
programmes. Later time of treatment onset improved the
cost-effectiveness across programmes. While discounting
and cost assumptions had some impact on the absolute
value of cost-effectiveness ratios, they did not change the
relative ranks of cost-effectiveness of different treatments.
CONCLUSION: Calcium and Alendronate are more
cost-effective treatments. As the population ages and
more people are subjective to risks of fracture due to
osteoporosis, policy formulating should consider the cost-
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OBJECTIVES: To identify and compare the cost-
effectiveness of raloxifene, alendronate and nasal calci-
tonin in the treatment of osteoporosis in postmenopausal
women in Poland.
METHODS: Model for the Polish health-care context
was developed, based on the use of clinical data from 
literature and local data of health-care resource utilisa-
tion and unit cost. Only the direct medical costs were
analysed. The perspective of health-care payers and time
horizon of 3 years was considered. The target population
were patients aged 68, without (group I) and with or
without (group II) previous vertebral fractures. The out-
comes measures were LYG and QALYs gained, calculated
on the basis of available evidence for a preventive effect
on a hip, vertebral, wrist and ankle fractures and breast
cancer risk. The cost-effectiveness threshold was calcu-
lated on the basis of 1-year haemodialysis treatment cost
(60,000 PLN, 1 USD = 4 PLN; in 2002). The one-way
and two-way sensitivity analysis was performed.
RESULTS: The highest effectiveness in terms of LYG and
QALYs was achieved with raloxifene treatment compared
to alendronate and calcitonin. Calcitonin was the least
effective and the most costly strategy. Incremental analy-
sis suggests that raloxifene compared with alendronate
gives additional effects for extra costs below suggested
cost-effectiveness threshold: the ICER was 35023
PLN/LYG and 31023 PLN/QALY gained in group I, and
45834 PLN/LYG and 40571 PLN/QALY gained in group
II. Sensitivity analysis showed that calcitonin remained
dominated strategy by comparators in all cases. Only
raloxifene price and incidence of breast cancer changes
have signiﬁcant effect on the ICER, placing it above the
cost-effectiveness threshold.
CONCLUSIONS: Given the results of the analysis, in
postmenopausal women calcitonin is less effective and
more costly than alendronate and raloxifene. Based on
current evidence, raloxifene appears to be cost-effective
when compared with alendronate and within a Polish
context offers substantial beneﬁt at reasonable cost.
